A Shocking Legal Blow for One of Big Pharma’s Giants
Merck & Co., Inc. (NYSE: MRK), one of the largest pharmaceutical companies in the world, is facing a class action lawsuit for alleged violations of federal securities laws. The claims revolve around misleading financial projections tied to the company’s flagship HPV vaccine, Gardasil. Investors who bought Merck stock between February 3, 2022, and February 3, 2025, now have until April 14, 2025, to consider joining the lawsuit and protecting their financial interests.
What Sparked the Lawsuit?
The core of the lawsuit lies in Merck’s bold projections regarding Gardasil’s growth. The company stated it was on track to reach $11 billion in annual revenue from the vaccine by 2030, citing global demand — particularly in China — as a key driver. Executives highlighted their strategy of consumer education and awareness campaigns to fuel growth.
But on February 4, 2025, Merck delivered news that shocked investors: Gardasil shipments to China would be suspended until at least midyear due to overstocked inventory levels. Demand in the region had fallen short, and Merck admitted it needed to drastically reduce vaccine inventory. That same day, Merck’s stock dropped sharply, plunging over 9% from $99.79 to $90.74 per share.
Investor Confidence Shaken
The revelation raised serious concerns about how Merck had communicated its business outlook. Investors and analysts questioned whether the company had knowingly overstated its expectations and failed to disclose critical inventory risks. These suspicions formed the basis of the class action complaint now filed by the law firm Levi & Korsinsky.
According to the lawsuit, Merck’s previous statements about Gardasil were materially misleading and failed to reflect the true state of demand and inventory challenges. Shareholders who purchased stock during the affected period and suffered losses are being encouraged to come forward before the legal deadline.
Time Is Running Out for Investors
The deadline for investors to join the lawsuit is fast approaching — April 14, 2025. Those eligible don’t need to serve as lead plaintiffs to participate in the class action. Joining could allow them to seek financial recovery from the alleged misconduct. There are no upfront fees or obligations for participating.
If you invested in Merck during the time in question and experienced losses, it’s essential to consider your legal rights and speak with an attorney or firm experienced in securities litigation. These class actions often move quickly, and missing the deadline could mean missing out on potential compensation.
Merck’s Market Outlook After the Drop
As of April 7, 2025, Merck’s stock continues to feel the impact of the lawsuit and supply chain news, trading at $80.85 — a further decline from its February levels. The extended selloff reflects lingering investor skepticism and broader concerns about how Merck will manage expectations moving forward.
Final Thoughts: Accountability and the Road Ahead
The Merck case underscores the risks that even the most established blue-chip companies face when transparency falters. While Gardasil remains a cornerstone product for Merck, the company’s handling of projections and market challenges is now under the legal spotlight.
Investors should stay informed, reassess their portfolios, and monitor further developments closely. Whether this lawsuit leads to a significant payout or changes in corporate governance, it’s a clear reminder of the importance of accountability in today’s markets.